Health Management Center, The Third Xiangya Hospital, Central South University, No. 138 Tongzipo Road, Yuelu District, Changsha, 410013, Hunan, China.
General Surgery Department, The Third Xiangya Hospital, Central South University, No.138 Tongzipo Road, Yuelu District, Changsha, 410013, Hunan, China.
Sci Rep. 2022 Aug 30;12(1):14786. doi: 10.1038/s41598-022-18988-x.
Non-alcoholic fatty liver disease (NAFLD) is a hepatic manifestation of metabolic syndrome (MetS), and the relationship between NAFLD and metabolic deterioration remains unclear. This study aimed to investigate dynamic changes in metabolically healthy phenotypes and to assess the impact of non-alcoholic fatty liver disease (NAFLD) on the conversion from metabolically healthy (MH) to metabolically unhealthy (MU) phenotypes across body shape phenotypes and phenotypic change patterns. We defined body shape phenotypes using both the body mass index (BMI) and waist circumference (WC) and defined metabolic health as individuals scoring ≤ 1 on the NCEP-ATP III criteria, excluding WC. A total of 12,910 Chinese participants who were MH at baseline were enrolled in 2013 and followed-up in 2019 or 2020. During a median follow-up of 6.9 years, 27.0% (n = 3,486) of the MH individuals developed an MU phenotype. According to the multivariate Cox analyses, NAFLD was a significant predictor of conversion from the MH to MU phenotype, independent of potential confounders (HR: 1.12; 95% confidence interval: 1.02-1.22). For the MH-normal weight group, the relative risk of NAFLD in phenotypic conversion was 1.21 (95% CI 1.03-1.41, P = 0.017), which was relatively higher than that of MH-overweight/obesity group (HR: 1.14, 95% CI 1.02-1.26, P = 0.013). Interestingly, the effect of NAFLD at baseline on MH deterioration was stronger in the "lean" phenotype group than in the "non-lean" phenotype group at baseline and in the "fluctuating non-lean" phenotype change pattern group than in the "stable non-lean" phenotype change pattern group during follow-up. In conclusion, lean NAFLD is not as benign as currently considered and requires more attention during metabolic status screening.
非酒精性脂肪性肝病 (NAFLD) 是代谢综合征 (MetS) 的肝脏表现,NAFLD 与代谢恶化之间的关系尚不清楚。本研究旨在探讨代谢健康表型的动态变化,并评估非酒精性脂肪性肝病 (NAFLD) 对不同体型表型和表型变化模式下从代谢健康 (MH) 向代谢不健康 (MU) 表型转变的影响。我们使用体重指数 (BMI) 和腰围 (WC) 来定义体型表型,并将符合 NCEP-ATP III 标准且 WC 除外评分≤1 的个体定义为代谢健康。共有 12910 名基线时代谢健康的中国参与者于 2013 年入组,并于 2019 年或 2020 年随访。在中位随访 6.9 年期间,34.86%(n=3486)的 MH 个体发展为 MU 表型。多变量 Cox 分析显示,NAFLD 是从 MH 向 MU 表型转变的重要预测因素,独立于潜在的混杂因素(HR:1.12;95%置信区间:1.02-1.22)。对于 MH-正常体重组,NAFLD 在表型转换中的相对风险为 1.21(95%CI 1.03-1.41,P=0.017),相对高于 MH-超重/肥胖组(HR:1.14,95%CI 1.02-1.26,P=0.013)。有趣的是,在基线时,NAFLD 对 MH 恶化的影响在“瘦”表型组中强于在基线时的“非瘦”表型组,在随访期间的“波动非瘦”表型变化模式组中强于在“稳定非瘦”表型变化模式组。总之,瘦型 NAFLD 并不像目前认为的那样良性,在代谢状态筛查时需要更加关注。